Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“Hot off the press – Pre-proof vesion.
Pleased to share our Editorial in European Society for Medical Oncology (ESMO) flagship journal Annals of Oncology
‘Next-Generation Sequencing Consensus Guidelines for Sarcoma: Progress, Gaps, and the Path Forward’
Razelle Kurzrock and I opine that ‘Consensus must accelerate our field, not delay it. For many sarcomas, genomics isn’t ancillary, it IS the DIAGNOSIS”
Huge congrats to Annals of Oncology for its exceptional leadership in the field standing as one of oncology’s most highly cited journals (IF 80+)”
Title: Next-Generation Sequencing Consensus Guidelines for Sarcoma: Progress, Gaps, and the Path Forward
Authors: V. Subbiah, R. Kurzrock
Other articles featuring Vivek Subbiah on OncoDaily.